| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SERTAD2 |
| Uniprot No | Q14140 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-314aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMLGKGGKRKFDEHEDGLEGKIVSPCDG PSKVSYTLQRQTIFNISLMKLYNHRPLTEPSLQKTVLINNMLRRIQEELK QEGSLRPMFTPSSQPTTEPSDSYREAPPAFSHLASPSSHPCDLGSTTPLE ACLTPASLLEDDDDTFCTSQAMQPTAPTKLSPPALLPEKDSFSSALDEIE ELCPTSTSTEAATAATDSVKGTSSEAGTQKLDGPQESRADDSKLMDSLPG NFEITTSTGFLTDLTLDDILFADIDTSMYDFDPCTSSSGTASKMAPVSAD DLLKTLAPYSSQPVTPSQPFKMDLTELDHIMEVLVGS |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SERTAD2重组蛋白的参考文献示例(部分为假设性内容，供参考格式)：
---
1. **标题**：*SERTAD2 promotes cell cycle progression by interacting with CDK4 in cancer cells*
**作者**：Smith J, et al. (2015)
**摘要**：研究通过重组表达人源SERTAD2蛋白，证实其与CDK4直接结合，加速G1/S期转换，促进肿瘤细胞增殖。
2. **标题**：*Structural characterization of recombinant SERTAD2 reveals a novel DNA-binding motif*
**作者**：Lee S, et al. (2020)
**摘要**：利用大肠杆菌系统表达并纯化SERTAD2重组蛋白，通过晶体学解析其三维结构，发现其C端含有独特的DNA结合域，可能参与转录调控。
3. **标题**：*SERTAD2 regulates p53 activity via ubiquitination pathways in stress response*
**作者**：Wang Y, et al. (2018)
**摘要**：在HEK293细胞中过表达重组SERTAD2蛋白，证明其通过泛素化修饰调控p53稳定性，影响细胞应激反应中的凋亡过程。
4. **标题**：*High-yield expression and purification of SERTAD2 recombinant protein for functional screening*
**作者**：Garcia R, et al. (2022)
**摘要**：优化昆虫细胞表达系统，实现SERTAD2重组蛋白的高效制备，并应用于高通量药物筛选，验证其作为癌症治疗靶点的潜力。
---
**备注**：上述文献为示例性质，实际研究中建议通过PubMed、Web of Science等数据库检索最新文献，或关注SERTAD2在癌症、细胞周期等领域的具体功能研究。
**Background of SERTAD2 Recombinant Protein**
SERTAD2 (SERTA domain-containing protein 2) is a member of the SERTA protein family, characterized by a conserved SERTA domain implicated in transcriptional regulation and protein-protein interactions. It is encoded by the *SERTAD2* gene, located on human chromosome 2q33.3. SERTAD2 functions as a transcriptional regulator, primarily interacting with components of the E2F-dependent pathways to modulate cell cycle progression, proliferation, and apoptosis. Studies suggest its involvement in stabilizing or enhancing the activity of E2F transcription factors, which are critical for G1/S phase transition and cellular differentiation.
Aberrant expression of SERTAD2 has been linked to cancer pathogenesis. Overexpression is observed in malignancies such as breast, colorectal, and lung cancers, where it promotes tumor growth, metastasis, and chemoresistance by dysregulating cell cycle checkpoints and apoptosis. Conversely, its downregulation in certain contexts may suppress oncogenic phenotypes, highlighting its context-dependent role.
Recombinant SERTAD2 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, biologically active forms for functional studies. This protein enables researchers to investigate its interactions with E2F family members, chromatin modifiers, or other regulatory partners in vitro. Applications include elucidating molecular mechanisms in carcinogenesis, screening for therapeutic inhibitors, or studying its role in developmental biology.
The availability of recombinant SERTAD2 also supports structural studies, antibody development, and high-throughput assays, providing tools to dissect its dual roles in normal physiology and disease. Its study holds potential for identifying novel biomarkers or targeted therapies in oncology.
×
